Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 9
1980 2
1981 4
1982 2
1983 1
1984 4
1986 1
1987 2
1988 8
1989 9
1990 5
1991 2
1992 8
1993 6
1994 8
1995 2
1996 2
1997 4
1998 4
1999 5
2000 8
2001 9
2002 3
2003 20
2004 27
2005 25
2006 28
2007 43
2008 52
2009 49
2010 42
2011 59
2012 73
2013 90
2014 71
2015 86
2016 87
2017 94
2018 112
2019 92
2020 138
2021 166
2022 157
2023 12
Text availability
Article attribute
Article type
Publication date

Search Results

1,490 results
Results by year
Filters applied: . Clear all
Page 1
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Zhu FC, et al. Among authors: li jx. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. Lancet. 2020. PMID: 32450106 Free PMC article. Clinical Trial.
Preface.
Li JX. Li JX. Adv Pharmacol. 2022;93:xiii-xiv. doi: 10.1016/S1054-3589(22)00014-X. Adv Pharmacol. 2022. PMID: 35341575 No abstract available.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Zhu FC, et al. Among authors: li jx. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, Chen Y, Hou LH, Liu JX, Zhong J, Pan HX, Shi FJ, Xu XY, Li ZP, Zhang XY, Cui LB, Tan WJ, Chen W, Zhu FC; CanSino COVID-19 Study Group. Li JX, et al. Lancet Respir Med. 2022 Aug;10(8):739-748. doi: 10.1016/S2213-2600(22)00087-X. Epub 2022 May 20. Lancet Respir Med. 2022. PMID: 35605625 Free PMC article. Clinical Trial.
Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling.
Li JX, Li RZ, Sun A, Zhou H, Neher E, Yang JS, Huang JM, Zhang YZ, Jiang ZB, Liang TL, Ma LR, Wang J, Wang XR, Fan XQ, Huang J, Xie Y, Liu L, Tang L, Leung EL, Yan PY. Li JX, et al. Pharmacol Res. 2021 Sep;171:105574. doi: 10.1016/j.phrs.2021.105574. Epub 2021 Jul 25. Pharmacol Res. 2021. PMID: 34419228
1,490 results